Enlicitide Chloride

Enlicitide Chloride, also known as MK-0616, is an oral PCSK9 inhibitor currently being studied in clinical trials. This article examines the ongoing research into this promising drug, focusing on its safety, tolerability, and effectiveness in various patient populations. We’ll explore how Enlicitide Chloride works in the body and its potential impact on cholesterol management.

Table of Contents

What is Enlicitide Chloride?

Enlicitide Chloride, also known by its research name MK-0616, is a new medication being developed to help manage cholesterol levels in the body[1]. It belongs to a class of drugs called PCSK9 inhibitors, which are designed to lower levels of harmful cholesterol in the blood[1].

How Does It Work?

Enlicitide Chloride works by targeting a protein in the body called PCSK9 (Proprotein Convertase Subtilisin Kexin 9). This protein plays a role in regulating cholesterol levels in the blood. By inhibiting or blocking PCSK9, Enlicitide Chloride helps to reduce the amount of harmful cholesterol circulating in your bloodstream[1].

What Conditions Does It Treat?

While the specific conditions that Enlicitide Chloride will be approved to treat are still being determined through clinical trials, it is being developed primarily to help manage high cholesterol levels. High cholesterol is a major risk factor for heart disease and stroke, so medications like Enlicitide Chloride could potentially help reduce the risk of these serious health problems[1].

How is It Administered?

One of the exciting aspects of Enlicitide Chloride is that it is being developed as an oral medication. This means it can be taken by mouth as a capsule, which is generally more convenient for patients than injections or infusions. In the clinical trials, a 10 mg capsule was used[1].

Current Clinical Studies

Enlicitide Chloride is currently undergoing several clinical trials to evaluate its effectiveness and safety. Two important studies are:

  1. Study in Participants with Moderate Renal Impairment: This study is looking at how Enlicitide Chloride works in people with moderately reduced kidney function. It’s important to understand how the medication behaves in these patients because many people with high cholesterol also have kidney problems[1].

  2. Metabolism and Excretion Study: This study is using a special technique with a radioactive label to track how Enlicitide Chloride moves through the body, how it’s broken down, and how it’s eliminated. This information is crucial for understanding the drug’s safety and how it should be dosed[2].

Safety and Side Effects

As with all medications, researchers are carefully monitoring the safety of Enlicitide Chloride. In the clinical trials, they are tracking any adverse events (side effects or unwanted reactions) that participants experience. So far, the studies have not reported any specific side effects, but it’s important to note that the full safety profile of the drug is still being established[1][2].

Future Prospects

Enlicitide Chloride represents an exciting development in cholesterol management. If proven effective and safe, it could offer several advantages:

  • It’s an oral medication, which is often preferred by patients over injections.
  • It targets PCSK9, a relatively new approach in cholesterol management that has shown promise in other drugs.
  • It’s being studied in people with kidney problems, which could make it a valuable option for patients with multiple health conditions.

However, it’s important to remember that Enlicitide Chloride is still in the testing phase. More research is needed before it can be approved for general use. Patients interested in new cholesterol treatments should discuss their options with their healthcare provider[1][2].

Aspect Details
Drug Name Enlicitide Chloride (MK-0616)
Drug Class PCSK9 Inhibitor
Administration Oral capsule
Study Populations Healthy adults, Chinese participants, individuals with moderate renal impairment
Primary Outcomes Safety, tolerability, pharmacokinetics, pharmacodynamics
Key Measurements Blood concentration over time, drug elimination rate, effects on LDL-C levels
Potential Benefits Lowering of LDL cholesterol levels
Current Stage Clinical trials (Phase 1 and beyond)

Ongoing Clinical Trials on Enlicitide Chloride

  • A Study of Enlicitide for Safety and Effectiveness in Children and Adolescents with Heterozygous Familial Hypercholesterolemia

    Recruiting

    1 1
    Investigated drugs:
    Belgium Czechia Finland France Germany Italy +4
  • A Study of Enlicitide and Rosuvastatin for Adults With High Cholesterol

    Recruiting

    1 1 1
    Hungary Spain
  • Study on the Effectiveness and Safety of MK-0616 for Adults with High Cholesterol

    Not recruiting

    1 1
    Investigated drugs:
    Germany Italy Spain
  • Study on MK-0616, Ezetimibe, and Bempedoic Acid for Adults with High Cholesterol

    Not recruiting

    1 1 1
    France Spain
  • Study on the Safety and Efficacy of MK-0616 for Adults with High Cholesterol

    Not recruiting

    1 1 1
    Investigated drugs:
    Czechia Finland France Germany Hungary Italy +3
  • Study on the Effectiveness of Enlicitide Chloride in Reducing Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease

    Not recruiting

    1 1
    Investigated drugs:
    Denmark France Germany Hungary Italy The Netherlands +3
  • Study of MK-0616 for Adults with Familial Hypercholesterolemia

    Not recruiting

    1 1
    Investigated drugs:
    Czechia Finland Hungary The Netherlands Norway Spain

Glossary

  • PCSK9 Inhibitor: A type of drug that blocks the action of PCSK9, a protein that reduces the liver's ability to remove LDL cholesterol from the blood. By inhibiting PCSK9, these drugs can help lower LDL cholesterol levels.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Area Under the Curve (AUC): A measure of the total exposure to a drug over time, often used in pharmacokinetic studies.
  • Maximum Plasma Concentration (Cmax): The highest concentration of a drug in the blood after administration.
  • Time to Maximum Plasma Concentration (Tmax): The time it takes for a drug to reach its highest concentration in the blood.
  • Half-life (t1/2): The time it takes for the concentration of a drug in the body to be reduced by half.
  • LDL-C: Low-density lipoprotein cholesterol, often referred to as 'bad' cholesterol. High levels of LDL-C are associated with an increased risk of heart disease.
  • Renal Impairment: A condition where the kidneys are not functioning properly, which can affect how drugs are processed and eliminated from the body.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.

References

  1. https://clinicaltrials.gov/study/NCT05070390
  2. https://clinicaltrials.gov/study/NCT06658626